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ABSTRACT
Introduction This study sought to compare the 
metabolomic, hormonal and physiological responses to 
hypoglycemia versus euglycemia during exercise in adults 
with type 1 diabetes (T1D).
Research design and methods Thirteen individuals with 
T1D (hemoglobin; 7.0%±1.3% (52.6±13.9 mmol/mol), age; 
36±15 years, duration diabetes; 15±12 years) performed a 
maximum of 45 min submaximal exercise (60%±6% V̇O2max). 
Retrospectively identified exercise sessions that ended in 
hypoglycemia ((HypoEx) blood glucose (BG)≤3.9 mmol/L) 
were compared against a participant- matched euglycemic 
condition ((EuEx) BG≥4.0, BG≤10.0 mmol/L). Samples were 
compared for detailed physiological and hormonal parameters 
as well as metabolically profiled via large scale targeted ultra- 
high- performance liquid chromatography coupled to tandem 
mass spectrometry. Data were assessed using univariate 
and multivariate analysis techniques with false discovery rate 
adjustment. Significant results were considered at p≤0.05.
Results Cardiorespiratory and counterregulatory hormone 
responses, whole- body fuel use and perception of 
fatigue during exercise were similar under conditions of 
hypoglycemia and euglycemia (BG 3.5±0.3 vs 5.8±1.1 
mmol/L, respectively p<0.001). HypoEx was associated 
with greater adenosine salvage pathway activity 
(5’-methylthioadenosine, p=0.023 and higher cysteine and 
methionine metabolism), increased utilization of glucogenic 
amino acids (glutamine, p=0.021, alanine, aspartate 
and glutamate metabolism and homoserine/threonine, 
p=0.045) and evidence of enhanced β-oxidation (lower 
carnitine p<0.001, higher long- chain acylcarnitines).
Conclusions Exposure to acute hypoglycemia during 
exercise potentiates alterations in subclinical indices of 
metabolic stress at the level of the metabolome. However, 
the physiological responses induced by dynamic physical 
exercise may mask the symptomatic recognition of mild 
hypoglycemia during exercise in people with T1D, a 
potential clinical safety concern that reinforces the need 
for diligent glucose management.
Trial registration number DRKS00013509.
INTRODUCTION
Despite the benefits of regular physical exer-
cise in aiding long- term glycemia control,1 the 
acute management of glucose during exer-
cise is challenging for those with T1D. The 
heightened metabolic demands of exercising 
skeletal muscle can potentiate increases in 
tissue glucose uptake through mechanisms 
independent of, but additive to, insulin.2 3 So 
to avoid disproportions in the rate of glucose 
disappearance with the rate of appearance, 
Significance of this study
What is already known about this subject?
 ► Physical exercise- related hypoglycemia is a major 
clinical concern in the glycemic management of 
people with type 1 diabetes (T1D).
 ► Although our pathophysiological understanding 
of hypoglycemia at rest is well established, less is 
known about the impact of hypoglycemia on physi-
ological, counterregulatory hormone, perceptual ef-
fort and bioenergetic responses to dynamic physical 
exercise in individuals with T1D.
What are the new findings?
 ► Under laboratory- controlled conditions, the phys-
iological, hormonal and metabolomic responses of 
participants who experienced hypoglycemia while 
performing aerobic exercise were compared with a 
euglycemic exercising condition.
 ► Combined with detailed physiological monitoring 
during exercise, a targeted ultra- high- performance 
liquid chromatography tandem mass spectrometry 
approach in the present study has provided new 
and additive insights of the physiological and bio-
energetic responses to exercise under conditions of 
hypoglycemia and euglycemia in people with T1D.
 ► Physiological and counterregulatory hormone re-
sponses, whole- body fuel use and perception of 
fatigue to exercise were similar under conditions of 
hypoglycemia and euglycemia; however, mild hypo-
glycemia during exercise was associated with signs 
of intracellular imbalance and an increased reliance 
on energy pathways involved in purine, lipid and 
amino acid metabolism.
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the body initiates a complex neuroendocrine interplay 
consisting of a decrement in insulin secretion (to suppress 
endogenous glucose utilization (EGU) via inhibition of 
glycogen phosphorylase) opposed by increments in the 
secretion of glucagon and the catecholamines (which aid 
endogenous glucose production (EGP) via glycogeno-
lysis and gluconeogenesis).4 5 However, notwithstanding 
an inability to autoregulate exogenously administered 
insulin concentrations, the hemodynamic alterations 
induced by aerobic exercise enhance the mobilization 
of insulin from the subcutaneous depot.6 7 Hence, the 
synergistic effects of insulin and exercise in enhancing 
EGU,8 yet suppressing EGP,9 predispose exercise- related 
hypoglycemia in T1D.10 11
Although several diabetes- specific recommendations 
for safe performance of physical exercise exist,12 13 the 
glycemic response to a given exercise session is highly vari-
able in people with T1D,14 thus predicting an expected 
glucose trend is difficult. The bioenergetic requirements 
of exercise are highly dependent on its relative intensity 
and endogenous fuel availability. During the initial stages 
of submaximal exercise, intramuscular glycogen serves as 
the prevailing source of energy, with a growing reliance 
on bloodborne glucose delivered from hepatic glycog-
enolysis and gluconeogenesis. However, in addition to 
attenuated glucose counterregulation,15–18 individuals 
with T1D also demonstrate diminished hepatic glycog-
enolysis during both hypoglycemia17 and exercise,19 with 
a supplementary reliance on gluconeogenesis to support 
EGP.19 These aberrations in substrate mobilization may 
contribute to the aberrant bioenergetic responses to 
exercise commonly observed in those with T1D.20 21
Due to the number of determinants involved in the 
control of fuel mobilization and metabolism during exer-
cise in people with T1D, assessing the metabolic response 
to exercise is undoubtedly complex. Although the influ-
ence of hyperinsulinemia,8 hyperglycemia22 and exercise 
modality23 on the metabolic responses to exercise in T1D 
have recently been investigated, less work has explored 
the potential implications of acute hypoglycemia during 
exercise on aspects of energy metabolism in people with 
T1D, not least because of the practical constraints of safe 
sample obtention. Given the importance of glucose as a 
major fuel to support exercising muscle tissue, hypogly-
cemia may significantly alter the rate and energetic means 
by which ATP is regenerated during exercise, particularly 
if combined with inadequate glucose counterregulation. 
Hence, alongside neurohormonal and physiological 
analyses, the integration of metabolic profiling tech-
niques that provide insight of energy pathway activity, 
may advance our current understanding of the metabolic 
responses to both exercise and hypoglycemia in T1D, 
and help inform appropriate treatment decisions in clin-
ical care.
Aim
To compare the metabolomic, hormonal and physiolog-
ical responses to hypoglycemia versus euglycemia during 
exercise in adults with type 1 diabetes (T1D).
RESEARCH DESIGN AND METHODS
Study design
This exploratory study involved a retrospective analysis 
of a single- centre, randomized, open- label, four- period 
crossover clinical trial consisting of 23 hours inpatient 
phases with a 45 min evening bout of semi- recumbent 
cycling at 60±6% V̇O2max. In the hour before and after 
exercise, participants administered either a full (100%) 
or reduced (50%) dose of individualized bolus insulin 
aspart alongside identical carbohydrate (CHO)- rich 
meals (1 g/CHO/kg/bm). Venous- derived samples were 
taken hourly leading into cycling, as well as immediately 
postexercise, then throughout the remaining 14- hour 
inpatient stay, including nocturnal hours. Trial day 
hypoglycemia as confirmed by a venous blood glucose 
(BG) value of ≤3.9 mmol/L. All participants were using 
unblinded interstitial glucose monitoring devices (Free-
style Libre, Abbott, Lake Bluff, Illinois, USA).
Inclusion and exclusion criteria
Main inclusion criteria were: diagnosis of T1D for ≥12 
months; age 18–65 years (both inclusive); body mass 
index of 18.0–29.4 kg.m2; use of multiple daily injections 
of insulin for ≥12 months; body mass- specific peak oxygen 
uptake of ≥20 mL/kg/min and a status of being physically 
active as assessed by the International Physical Activity 
Questionnaire Short Form. Main exclusion criteria were: 
presence of a life- threatening disease (ie, proliferative 
retinopathy or maculopathy, severe neuropathy), recur-
rent severe hypoglycemia (>1 severe hypoglycemia event 
during the previous 12 months), hypoglycemia unaware-
ness, hospitalization for diabetic ketoacidosis during 
the previous 6 months, any other condition that would 
interfere with trial participation or evaluation of results 
as judged by the investigators.
Trial design
As part of a retrospective design using a same- person 
comparison, the postexercise BG value from each of the 
four crossover experimental arms was used to identify 
participants whom on one occasion ended exercise while 
hypoglycemic ((HypoEx) BG ≤3.9 mmol/L), and on one 
of the other three trials finished exercise while eugly-
cemic ((EuEx) BG ≥4.0, BG≤10.0 mmol/L).24 The first 
Significance of this study
How might these results change the focus of research or 
clinical practice?
 ► Hypoglycemia during exercise potentiates alterations in subclinical 
indices of metabolic stress at the level of the metabolome. However, 
the physiological responses induced by acute dynamic exercise 
may mask the symptomatic recognition of hypoglycemia during 
exercise in people with T1D, a potential clinical safety concern that 
reinforces the need for diligent glucose management.
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selection criteria for the comparative euglycemic sample 
was that which was matched in the pre- exercise bolus 
insulin dosing manipulation, that is, the PreEx100%-
PostEx100% arm was paired with the PreEx100%-
PostEx50% arm, while the PreEx50%-PostEx50% arm 
was paired with the PreEx50%-PostEx100% arm. Failing 
that, the arm with the highest BG value still within the 
euglycemic range was selected over a trial that was closer 
to the hypoglycemic threshold. Of a possible 16 individ-
uals who completed all 4 experimental visits, the data 
from 13 individuals were suitable for inclusion in this 
exploratory study.
Moderate-intensity continuous exercise testing protocol and 
hypoglycemia identification
The evening (17:00) exercise test consisted of maximum 
of 45 min (3 min warm- up at 20 W, 42 min at target 
workload) of continuous cycling on a semi- recumbent 
ergometer (Corival Recumbent, Lode, The Nether-
lands) at 60±6% V̇O2max. The target workload intensity 
was computed as the mid- point between the first and 
second lactate turn points. Participants were instructed 
to maintain a stable pedal cadence between 65 and 75 
revolutions per minute (RPM) against a fixed workload. 
During exercise, heart rate (HR (s410, Polar, Finland)), 
respiratory (METAMAX 3B; Cortex Biophysik GmbH, 
Germany) and power metrics were collected in an inte-
grative nature and measured continuously. The 60 s aver-
ages of 5 s intervals were used to determine gas exchange 
variables rates at rest, following the warm- up, at each 6 
min interval over the target workload, and immediately 
prior to exercise cessation. Rates of CHO and lipid oxida-
tion were determined via indirect calorimetry using the 
stoichiometric equations suitable for moderate- intensity 
exercise as described previously.25 O2 pulse was calcu-
lated as the O2/HR ratio. In addition to a 4 μL fingertip 
BG measurement (used for safety purposes and assessed 
immediately via the built- in glucometer (Freestyle libre)), 
a 20 μL capillary blood sample was collected every 6 
min from the right earlobe and used for within exer-
cise glucose and lactate analysis via the fully enzymatic- 
amperometric method ((FEA) Biosen C- Line, EKF 
Diagnostic, Germany). Rate of perceived exertion (RPE 
(Borg scale)) was also captured every 6 min. If fingertip 
BG reached ≤3.9 mmol/L prior to completion of the 
full 45 min test protocol, exercise testing was terminated 
immediately. At this point, a venous blood sample was 
drawn instantly and measured for BG and lactate (BLa). 
In the event of hypoglycemia, participants received a 
standardized CHO gel as a rescue aid (Glucogel, BBI 
Healthcare, UK) and were monitored to ensure recovery 
to euglycemic levels.
Venous-derived biomarker analysis
The Randox Daytona Plus RX series analyzer (Randox 
Laboratories, UK) was used for in vitro determination 
of β-hydroxybutyrate ((β-OHB) RB4067). ELISAs were 
used for the quantification of plasma glucagon (DGCG0, 
R&D Systems, Minneapolis, USA) and catecholamines 
(epinephrine (EPI) and norepinephrine (NE) ECT31- 
K02, Eagle Biosciences, New Hampshire, USA)). BG and 
BLa were analyzed via FEA.
Metabolomic sample preparation
To assess the metabolomic responses to exercise- induced 
hypoglycemia, a metabolic profile of EDTA plasma was 
acquired by a targeted ultra- high- performance liquid 
chromatography (reversed phase) coupled to tandem 
mass spectrometry (UHPLC- MS/MS) approach. Samples 
were thawed, vortexed and 2×100 μL plasma were trans-
ferred into two 96- well plates (1× for large- scale targeted 
MV026, 1× back- up). The protein precipitation and 
metabolite extraction were conducted with addition of 
300 μL of cold acetonitrile:ethanol 1:1 (volume/volume) 
containing internal standards. After vortexing, 250 μL of 
clear supernatant was transferred into a new 96- well plate 
and dried using speed vacuum. On the day of analysis, 
samples were reconstituted in 200 μL of 10% methanol 
in water containing 1 μg/mL chlorpropamide (dilution 
factor 1:2), vortexed, sonicated for 4 min in a water bath 
and centrifuged at 4400 g for 20 min at 4°C. The superna-
tants (150 μL) were transferred into a new 96- well plate 
and a quality control was prepared pooling 5 μL of each 
sample. An additional 2×100 μL of serum were extracted 
and the dried sample was reconstituted in 200 μL (1:2) 
and 400 μL (1:4) prior to analysis.
UHPLC-MS/MS analysis
Samples were analyzed in a randomized block design 
order on a triple quadrupole mass spectrometer (Xevo 
TQ- S, Waters) coupled to an UPLC Acquity I- Class system 
(Waters) by reversed- phase chromatography. Samples 
were first analyzed in negative electrospray ionization 
(ESI) mode followed by positive ESI mode and finally by 
selected reaction monitoring.
Statistical analysis
All statistical analyses were carried out using IBM SPSS 
V.26.0 (IBM, Armonk, New York, USA) and R V.3.6.1 
(The R Foundation for Statistical Computing, Vienna, 
Austria). Forward stepwise linear regression was used to 
explore relationships between trial arm glycemia and its 
metabolic marker. End of exercise data were assessed by 
means of univariate analysis with exercise duration, pre- 
exercise insulin dose amounts (inclusive of basal and 
bolus amounts), insulin arm (full or reduced dose) and 
the paring factor accounted for as covariates in the model. 
False data recovery adjustment was used for the correc-
tion of multiple testing. A repeated measures analysis of 
variance on three levels was conducted with Bonferroni- 
corrected pairwise comparisons used to examine time 
effects. Pearson’s correlations were used to explore asso-
ciations between metabolomic, and hormonal data based 
on glycemic grouping. Non- parametric equivalents were 
used when necessary. P values of ≤0.05 were considered 
to be statistically significant. The raw mass spectrometric 
copyright.
 o
n
 O
ctober 8, 2020 at Swansea University. Protected by
http://drc.bmj.com/
BM
J O
pen Diab Res Care: first published as 10.1136/bmjdrc-2020-001577 on 5 October 2020. Downloaded from 
4 BMJ Open Diab Res Care 2020;8:e001577. doi:10.1136/bmjdrc-2020-001577
Metabolism
data were processed with Skyline (V.19.1, MacCoss Lab). 
The peak area data of positive and negative ionization 
mode were combined. The prominence of circulating of 
metabolites in relation to glycemic grouping was assessed 
via cluster analysis, while partial least squares- discriminant 
analysis was performed to map the inter- relationships 
between all input- output data. Cross- tabulation analysis 
was used to identify estimated risk ratios (ERR) between 
nominal variables, with Fisher’s exact test used to report 
significance.
RESULTS
The baseline characteristics of study participants are 
detailed in table 1.
There were no differences between trials in the total 
daily dose of insulin ((inclusive of basal and bolus doses) 
HypoEx 44±23 vs EuEx 45±23 U, p=0.395) or total CHO 
intake (HypoEx 243±38 vs EuEx 242±41 g, p=0.961) 
taken in the hours leading into exercise. Trials were also 
identical in the amount of bolus insulin taken in the 
immediate hour prior to exercise (HypoEx; 4±2 (31% 
dose reduction) vs EuEx; 4±3 U (38% dose reduction), 
p=0.674), which was injected alongside the consumption 
of identical CHO rich meals (1 g/CHO/kg/bm). BG 
concentrations were similar at baseline (HypoEx 5.8±1.3 
vs EuEx 6.6±1.8 mmol/L, p=0.206) and immediately 
pre- exercise (HypoEx 7.6±2.3 vs EuEx 9.5±2.5 mmol/L, 
p=0.058).
Physiological and metabolic responses to acute moderate-
intensity continuous exercise
The physiological responses at rest, as an exercising mean 
during the target workload, and immediately at the end 
of exercise are presented in table 2. There were no differ-
ences between groups in any physiological parameter in 
any of the identified timepoints. Hypoglycemia trended 
towards slightly earlier test termination (HypoEx 38±8 vs 
EuEx 44±3 min, p=0.05).
Glycemic, metabolic and counterregulatory hormonal 
responses to exercise
Table 3A details the change in metabolic and counter-
regulatory hormonal biomarkers in response to exer-
cise, while table 3B displays the point concentrations in 
biomarkers immediately postexercise.
End of exercise BG concentrations were significantly 
lower during HypoEx (table 3, p<0.001). Neither the 
magnitude of the drop (table 3) nor the rate of change 
(HypoEx −0.11±0.06 vs EuEx −0.08±0.05 mmol/L/min, 
p=0.700) in BG differed between trials. There were no 
other differences between groups in either the exercise- 
induced change (table 3) or end of exercise concen-
trations (table 3) in metabolic and counterregulatory 
hormonal biomarkers.
The exercise- induced change in EPI (r=−0.612, 
p=0.026), NE (r=−0.902, p<0.001) and β-OHB (r=−0.685, 
p=0.010) were all inversely related to the exercise- induced 
change in BG during hypoglycemia but not euglycemia. 
Additionally, end of exercise EPI (r=−0.669, p=0.012), 
NE (r=−0.576, p=0.039), glucagon (r=−0.751, p=0.005), 
β-OHB (r=−0.559, p=0.039) and BLa (r=−0.621, p=0.023) 
concentrations were all inversely related to end of exer-
cise BG under conditions of hypoglycemia only.
Metabolomic responses to submaximal exercise
Figure 1 provides a multipictorial overview of the systemic 
metabolic changes during exercise under conditions of 
hypoglycemia and euglycemia in people with T1D using a 
targeted UHPLC- MS/MS approach. In total, 87 metabo-
lites were detected, 55 in positive ion mode, 27 in negative 
ion mode and 5 in both modes. Specifically, the cluster of 
1’-methylnicotinamide, L- methionine, citrulline, L- glu-
tamine, pyridoxamine and glucose corresponded to a 
visible separation between HypoEx and EuEx. Another 
small cluster was formed by 5’-methyladenosine and 
cytidine (figure 1B). These results were confirmed from 
the univariate analysis (figure 1C−E). Further pathway 
enrichment analysis using the Metaboanalyst platform 
defined the difference between HypoEx and EuEx to be 
characterized from cysteine and methionine metabolism 
as well as alanine, aspartate and glutamate metabolism.
Figure 2A details the correlation- based metabolic 
network analysis. Variable closer together have high 
correlations among them while those opposite have high 
negative correlations. Variables in the outer circle are the 
most relevant in driving the HypoEx- EuEx separation. 
Figure 2B displays the discriminating metabolites that 
differed significantly between groups at the point of exer-
cise cessation.
HypoEx was associated with higher 5’-methylthioade-
nosine (fold change: 1.468±0.515, 95% CI 1.262 to 1.674, 
p=0.023) and L- homoserine/L- threonine (fold change: 
1.108±0.230, 95% CI 1.016 to 1.200, p=0.045), but lower 
L- glutamine (fold change: 0.898±0.088, 95% CI 0.863 to 
Table 1 Baseline characteristics of study participants
Characteristic n=13
Gender M, F (n) 11 to 2
Age (years) 36±15
BMI (kg.m2) 26.8±3.3
HbA1c (%) 7.0±1.3
HbA1c (mmol/mol) 52.6±13.9
Diabetes duration (years) 15.3±12.1
Prestudy TDD (U/kg/bm) 0.6±0.3
Prestudy TDBD (U/kg/bm) 0.4±0.2
V̇O2max (mL/kg/min) 39.2±11.0
Data are presented as mean±SD.
bm, body mass; BMI, body mass index; F, female; HbA1c, 
hemoglobin A1c; M, male; n, number of participants; TDBD, total 
daily basal insulin dose; TDD, total daily insulin dose (inclusive of 
basal and bolus amounts); U, units of insulin; V̇O2max, maximum 
volume of inhaled oxygen.
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0.933, p=0.021) and L- carnitine (fold change: 0.837±0.123, 
95% CI 0.788 to 0.886, p<0.001) concentrations (figure 2B).
DISCUSSION
This novel, exploratory study characterized the physio-
logical, pancreatic/counter regulatory hormone and 
metabolomic responses to euglycemic exercise in adults 
with T1D and compared them with an exercise session 
that resulted in hypoglycemia. Combined with detailed 
physiological monitoring during exercise, integration 
of an UHPLC- MS/MS platform provided new and addi-
tive insights into the influence of hypoglycemia and 
Table 2 The physiological responses to exercise
Parameter Rest Exercise End of exercise
End of exercise p 
value
V̇O2 (L/min)
  Euglycemia 0.405±0.088 1.87±0.36* 1.958±0.420* 0.889
  Hypoglycemia 0.343±0.085 1.85±0.38* 1.860±0.400*
V̇CO2 (L/min)
  Euglycemia 0.36±0.08 1.77±0.06* 1.85±0.42* 0.835
  Hypoglycemia 0.31±0.07 1.76±0.36* 1.75±0.35*
Respiratory exchange ratio (L/min)
  Euglycemia 0.90±0.03 0.95±0.03* 0.94±0.03* 0.954
  Hypoglycemia 0.91±0.07 0.95±0.03* 0.94±0.04*
Carbohydrate oxidation (g/min)
  Euglycemia 0.3±0.1 1.9±0.5* 2.0±0.6* 0.786
  Hypoglycemia 0.3±0.1 1.9±0.4* 1.9±0.4*
Lipid oxidation (g/min)
  Euglycemia 0.069±0.023 0.17±0.08* 0.185±0.845* 0.811
  Hypoglycemia 0.058±0.040 0.15±0.07* 0.189±0.117*
Oxygen pulse (mL/beat)
  Euglycemia 0.007±0.005 0.01±0.00* 0.01±0.00* 0.269
  Hypoglycemia 0.003±0.005 0.01±0.00* 0.01±0.00*
Minute ventilation (L/min)
  Euglycemia 14.2±2.4 52.2±9.2* 55.5±11.6* 0.852
  Hypoglycemia 12.3±2.2 52.1±9.9* 52.8±8.9*
Tidal volume (L/min)
  Euglycemia 0.69±0.16 1.68±0.41* 1.71±0.46* 0.925
  Hypoglycemia 0.66±0.12 1.74±0.42* 1.69±0.45*
End- tidal oxygen partial pressure (mm Hg)
  Euglycemia 109.60±2.91 107.42±3.21* 108.36±4.16 0.460
  Hypoglycemia 109.88±6.15 106.21±4.24* 106.75±4.56*
End- tidal carbon dioxide partial pressure (mm Hg)
  Euglycemia 35.37±2.59 38.02±2.69* 37.01±3.32 0.919
  Hypoglycemia 34.25±3.59 38.23±3.59* 37.33±3.61*
Pedal revolutions per minute (revolutions/min)
  Euglycemia 0±0 71±6* 72±8* 0.215
  Hypoglycemia 0±0 68±7* 66±10*
Heart rate (bpm)
  Euglycemia 75±9 136±13* 142±14* 0.438
  Hypoglycemia 77±13 136±14* 145±16*
Rate of perceived exertion (Borg scale)
  Euglycemia 6±3 11±2* 12±3* 0.150
  Hypoglycemia 6±0 10±2* 13±3*
Data are presented as mean±SD (n=13). Spirometry data are reported as the 60 s mean of 5 s data points over each 6 min time interval.
Data have been treated via univariate analysis with exercise duration, pre- exercise insulin dosing amount (inclusive of all basal and bolus doses) and the insulin 
dosing arm (ie, full vs reduced dose) included as covariates in the model.
*P≤0.05 in the comparison with the resting value.
V̇CO2, volume of exhaled carbon dioxide; V̇O2, volume of inhaled oxygen.
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euglycemia during exercise on the activity of diverse 
metabolic pathways in people with T1D.
Autonomic system activation during exercise, princi-
pally an increase in sympathetic activity, and withdrawal 
of parasympathetic activity, is critical in facilitating stim-
ulation of several cardiovascular and hemodynamic 
processes aimed at maintaining glucose and oxygen 
supply to exercising muscle tissue in the face of increasing 
intracellular energy demands.26 27 Interestingly, many of 
the physiological responses to dynamic exercise share 
similar characteristics with the symptomatic responses 
to acute hypoglycemia (ie, sympathetic neural activa-
tion, sweating, pallor, elevated heart rate, observations of 
central and peripheral fatigue).28 Thus, it could be postu-
lated that the concurrent appearance of two physiological 
stressors (ie, exercise and hypoglycemia) would produce 
greater physiological, metabolic and counterregulatory 
responses than those induced by exercise and/or hypo-
glycemia per se. However, despite significant differences 
in the BG values at the point of sample obtention (~3.5 
vs 5.8 mmol/L), we found no influence of hypoglycemia 
on the cardiorespiratory responses, whole- body fuel use 
or the perception of effort to the same power output. 
Hence, it could be possible that for the exercising indi-
vidual with T1D, the simultaneous occurrence of exercise 
and hypoglycemia may somewhat hinder the ability to 
clearly disseminate symptoms that are exclusive to hypo-
glycemia per se, versus those which are being driven by 
the physiological strain of dynamic physical exercise per 
se. Importantly, none of the participants in the present 
study were hypoglycemic unaware, thus it is intriguing 
to think of how these responses may have differed in a 
cohort with such a diagnosis.
The BG value at the end of exercise in hypoglycemic 
arm fell within the bracket of level 1 hypoglycemia (≥3.0 
to ≤3.9 mmo/L) in people with T1D.29 30 Although this 
was significantly greater than the equivalent euglycemic 
value, the glycemic threshold for glucose counterregu-
lation in people with T1D is highly individualized and 
related to the degree of hypoglycemic awareness.31 Strict 
glycemic control in order to attain target hemoglobin 
A1c (HbA1c) (~7.1%) can lower the plasma glucose level 
required to generate a counterregulatory hormone 
response to concentrations deemed severely hypogly-
cemic (~2.6 mmol/L), and hence, diminish patient 
recognition of moderate hypoglycemia.32 Thus, the 
immediate correction of mild (≤3.9 mmo/L), as opposed 
to severe (<3.0 mmol/L), hypoglycemia in the present 
study may explain the similarities in our neurohormonal 
data, by virtue of our threshold being set ‘too high’, 
particularly given the appreciable glycemic control of 
our participants (HbA1c of ~7.0%). This may also explain 
the observed presence of inverse relationships between 
BG and the counterregulatory hormones in the hypogly-
cemic arm only, emphasizing the growing importance 
of these biomarkers in aiding EGP as glucose declines 
towards level 2, but not necessarily level 1, hypoglycemia.
Indeed, we observed no discernible differences in 
either glucagon or catecholamine concentrations under 
exercising conditions of hypoglycemia and euglycemia, 
suggesting a failure of mild hypoglycemia to induce suffi-
cient glucose counterregulation in people with T1D, an 
established finding within literature.17 19 33 The hormonal 
regulatory effects on gluconeogenesis and glycogenolysis 
during exercise have been studied extensively, and as per 
the key principles of glucose counterregulation at rest, 
a low insulin:glucagon ratio is essential in potentiating 
EGP to avoid and/or rapidly correct hypoglycemia.34–36 
In the current study, our participants likely exercised 
while hyperinsulinemic, having injected an individual-
ized dose of bolus insulin aspart 60 min prior to cycling 
that is directly within its peak action (~31–70 min),37 
alongside the consumption of a carbohydrate- rich meal 
(65% carbohydrate content), the latter of which prompts 
the muscle to preferentially use glucose as a source fuel.38 
This may then explain the comparability between groups 
in both the rate and magnitude of the drop in glucose 
(both of which were substantial), the presiding contri-
bution of carbohydrate oxidation to the total energy 
yield (HypoEx 85% vs EuEx 83%, p=0.896), and the 
inadequate counterregulatory hormonal responses to 
Table 3 End of exercise venous derived biomarker 
concentrations for the hypoglycemia (HypoEx) versus 
euglycemia (EuEx) trials
(A) Exercise- induced change in biomarkers
Biomarker HypoEx EuEx P value
Blood glucose 
(mmol/L)
−4.1±2.5* −3.6±2.2* 0.698
Blood lactate 
(mmol/L)
+1.8±0.0.9* +2.0±1.8* 0.916
β-OHB (mmol/L) +0.01±0.01 +0.01±0.02 0.945
Glucagon (pg/mL) +16.8±64.8 +1.6±13.0 0.348
EPI (nmol/L) +0.05±0.08 +0.03±0.12 0.779
NE (nmol/L) +0.63±1.11 +0.77±1.33 0.878
(B) End of exercise point concentrations in biomarkers
Biomarker HypoEx EuEx P value
Blood glucose 
(mmol/L)
3.5±0.3 5.8±1.1 <0.001
Blood lactate (mmol/L) 2.7±0.9 3.0±1.9 0.812
β-OHB (mmol/L) 0.05±0.01 0.05±0.02 0.945
Glucagon (pg/mL) 28.5±61.04 36.7±72.1 0.964
EPI (nmol/L) 0.08±0.09 0.08±0.13 0.817
NE (nmol/L) 1.37±0.93 1.45±1.49 0.635
Data are reported as mean±SEM; n=13.
Data have been treated via univariate analysis with exercise 
duration, pre- exercise insulin dosing amount (inclusive of all basal 
and bolus doses) and the insulin dosing arm (ie, full vs reduced 
dose) included as covariates in the model.
*P≤0.05 denotes significant difference compared with the 
corresponding immediate pre- exercise value.
EPI, epinephrine; Ex, exercise; NE, norepinephrine; β-OHB, 
β-hydroxybutyrate.
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both exercise and hypoglycemia as separate, and combined, 
entities.
Undoubtedly, physical exercise is an intense physiolog-
ical and metabolic stress and requires the integration of 
multiple organ systems to coordinate the utilization of 
intracellular and extracellular energy stores to support 
ATP resynthesis.39 Thus, the use of metabolomics in 
the present study provided further detailed insights of 
the metabolic responses to exercise under conditions 
of hypoglycemia and euglycemia in people with T1D. 
The elevated concentrations of metabolites involved in 
purine metabolism during hypoglycemia ((figure 1B), 
particularly those involved in the salvage pathway, ie, 
5'-methylthioadenosine (figure 2B)) imply a higher rate 
of intracellular ATP turnover.40 41 MTA is rapidly metab-
olized by 5’-methythioadenosine phosphorylase to yield 
adenine and 5- methylthioribose-1- phosphate (MTR1P). 
MTR1P is subsequently converted to methionine while 
the adenine molecule is salvaged to replenish the AMP 
and ATP pools.42 Hypoglycemia during exercise was also 
associated with significant decrements in plasma levels of 
carnitine and visual increases in clusters of several long- 
chain (C14–C18) acylcarnitines, suggesting enhanced 
β-oxidation. Carnitine is responsible for the translocation 
Figure 1 (A) Schematic representation of the experiment. (B) Heat- plot depicting separation quality of hypoglycemia (HypoEx) 
versus euglycemia (EuEx) at the point of exercise cessation. Some pattern of differences between metabolites for HypoEx 
versus EuEx is revealed via k- means clustering. Specifically, the cluster of 1’-methylnicotinamide, L- methionine, citrulline, L- 
glutamine, pyridoxamine and glucose corresponds to a visible separation between hypoglycemia and euglycemia. Another 
small cluster was formed by 5’-methyladenosine and cytidine. These results were confirmed from the univariate analysis (C–E). 
Further pathway enrichment analysis using the metaboanalyst platform defined the difference between HypoEx and EuEx to be 
characterized from cysteine and methionine metabolism as well as alanine, aspartate and glutamate metabolism. UHPLC- MS/
MS, ultra- high- performance liquid chromatography (reversed phase) coupled to tandem mass spectrometry.
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of long- chain acyl coenzyme A (CoA) (derived from circu-
lating lipids) into the mitochondrial matrix where they 
undergo oxidation to form acetyl CoA to enter the tricar-
boxylic acid (TCA) cycle for energy generation.43 Finally, 
during in- exercise hypoglycemia we observed lower 
concentrations of various glucogenic amino acids (partic-
ularly methionine and glutamine), which can be biolog-
ically degraded to form intermediates of the TCA cycle, 
and latterly used for gluconeogenesis. These findings 
were supported by our pathway analysis which detailed 
higher alanine, aspartate and glutamate metabolism as 
well as cysteine and methionine metabolism, indicating 
higher amino acid metabolism during hypoglycemia. 
The cysteine produced via methionine metabolism can 
be used for the biosynthesis of glutathione, a major anti-
oxidant involved in the direct scavenge of radical species 
to counteract oxidative stress.44 Hence, our data reaffirm 
the pro- oxidative effects of hypoglycemia in people with 
T1D,45 but expand these rested findings to a dynamic 
exercising environment. The metabolomic signature of 
hypoglycemia during exercise in the present study was 
similar to that commonly observed in response to energy- 
depleting exercise23 46 and/or nutritional deprivation, 
that is, fasting.47 48 Taken collectively, hypoglycemia 
during exercise was associated with signs of intracellular 
imbalance and a consequential increase in the activity 
of energy pathways involved in purine, lipid and amino 
metabolism.
Although individual metabolites may function as bioac-
tive effectors, their upstream biochemical pathways are 
often tightly orchestrated by hormonal shifts.47 While we 
did not observe any overt hormonal differences between 
conditions when assessed as point concentrations, there 
was a trend for more pronounced glucagon (HypoEx; 
+144% vs EuEx +4%) and epinephrine (HypoEx; +195% 
vs EuEx +71%) responses to exercise in the hypoglycemic 
arm. Glucagon and epinephrine promote EGP via glycog-
enolysis, gluconeogenesis and lipolysis (the latter via the 
hydrolysis of triglycerides to yield glycerol (which can be 
used to support gluconeogenesis) and free fatty acids 
(which undergo the process described above)).49 Thus, 
it is tempting to speculate that the greater responsiveness 
of these two hormones during hypoglycemia, may at least 
partly, explain the divergence in our metabolomic obser-
vations, although this hypothesis warrants future explo-
ration. On reflection, it would seem as though while the 
exposure to acute, level 1 hypoglycemia during exercise 
may not have been of sufficient duration nor depth to 
have provoked a potent enough hormonal response, it 
did appear to potentiate alterations in subclinical indices 
of metabolic stress at the level of the metabolome.
The high carbohydrate feeding plan leading into exer-
cise in our study the provides reasonable confidence in 
stating the unlikeliness of significant glycogen deple-
tion over the 45 min submaximal exercise test. It is then 
interesting to note that hypoglycemia led to an increased 
utilization of non- carbohydrate containing precursor 
molecules involved in gluconeogenesis. Previous research 
has documented attenuated rates of hepatic glycogeno-
lysis during both hypoglycemia17 and exercise19 in people 
with T1D, a deficit that is supplemented by excessive rates 
of hepatic gluconeogenesis.19 These alterations in fuel 
mobilization are believed contributory to the increased 
risk of recurrent hypoglycemia and hypoglycemia- 
associated autonomic failure (HAAF) commonly 
observed in T1D. This led us to perform subanalysis on 
Figure 2 Results from multivariate analysis via principle component analysis (A) and box plots of significant metabolites (B) 
revealed via univariate analyses based on standard linear modeling. E, euglycemia; H, hypoglycemia.
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our data to assess the potential risk of recurrent events. 
We found that antecedent exercise- induced hypogly-
cemia was associated with a 1.5- fold increase in the risk of 
recurrent hypoglycemia in the acute (~6 hours) postex-
ercise period (HypoEx 5 events vs EuEx 1 event, ERR; 1.5 
(95% CI 0.959 to 2.370), p=0.06). This was corroborated 
by a noticeable increase in the amount of time spent in 
the interstitial- derived hypoglycemic range leading into 
and throughout the nocturnal hours (HypoEx 2.5±4.6% 
vs EuEx 0.2%±0.5%, p=0.07), findings with clear clinical 
relevance. It is well established that antecedent hypogly-
cemia can attenuate the counterregulatory mechanisms 
against a subsequent event,50 51 thereby exposing the 
individual to a vicious cycle of recurrent hypoglycemia—
the classic features of HAAF. The concept of HAAF 
has recently been expanded to an exercise component 
(EAAF), with the acknowledgment that antecedent exer-
cise itself may impair the counterregulatory defenses 
to subsequent hypoglycemia.52 53 Hence, using a model 
during which exercise and hypoglycemia occurred simul-
taneously, our current findings underline the escalation 
in the risk of recurrent hypoglycemia when the princi-
ples of HAAF and EAAF are combined, reaffirming the 
importance of diligent glucose monitoring around exer-
cise in people with T1D.
Study strengths, limitations and future recommendations
The application of a validated UHPLC- MS/MS metab-
olomic profiling platform, combined with counterreg-
ulatory hormonal and physiological analyses under 
controlled laboratory conditions has provided novel 
insights in the provision and partition of fuel during 
exercise under conditions of both level 1 hypoglycemia 
and euglycemia in people with T1D. However, in addition 
to a small sample size, the homogeneity of study partici-
pants including the predominately male gender split, the 
appreciable glycemic control and the immediate correc-
tion of hypoglycemia at a high threshold are important 
points for consideration when interpreting findings. 
Further work is needed to deepen our understanding of 
the influence of hypoglycemia during exercise on various 
aspects of human physiology in people with T1D.
CONCLUSION
Exposure to acute hypoglycemia during exercise poten-
tiates alterations in subclinical indices of metabolic stress 
at the level of the metabolome. However, the physiolog-
ical responses induced by dynamic physical exercise may 
mask the symptomatic recognition of mild hypoglycemia 
during exercise in people with T1D, a potential clinical 
safety concern that emphasizes the need for increased 
attention to glucose management.
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